Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Verapamil Induced Gingival Enlargement in Cluster Headache
JNNP 76:124-127, Matharu,M.S.,et al, 2005
Multifocal Myoclonus Due to Verapamil Overdose
Neurol 58:984-985, Vadlamudi,L.&Wijdicks,E.F.M., 2002
Medically Induced Gingival Hyperplasia
Mayo Clin Proc 73:1196-1199, Meraw,S.J. &Sheridan,P.J., 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993
Cortical Blindness after Nifedipine Treatment
BMJ 305:693, Morton,C.&Hickey-Dwyer,M., 1992
Early Treatment of Ischemic Stroke with a Calcium Antagonist
Stroke 22:437-441, Rosenbaum,D.,et al, 1991
Interactions Between Calcium Channel Blockers and the Anticonvulsants Carbamazepine and Phenytoin
Neurol 41:740-742, Bahls,F.H.,et al, 1991
Calcium Antagonists:Stroke Therapy Coming of Age
Stroke 21:494-501, Wong,M.C.W.&Haley,E.C., 1990
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Nifedipine in the Prophylaxis of Classic Migraine:A Crossover, Double-Masked, Placebo-Controlled Study of Headache
Neurol 39:284-286, McArthur,J.C.,et al, 1989
Nifedipine and Myoclonic Disorders
Nephron 51:281, Pedro-Botet,M.L.,et al, 1989
Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
J Stroke Cerebrovasc Dis 29:105216, Jugita, Y.,et al, 2020
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Management of Bleeding in Patients Taking Oral Anticoagulants
JAMA 319:2032-2033, Anderson, I.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Association of Antithrombotic Drug Use with Subdural Hematoma Risk
JAMA 317:836-846, Gaist, D.,et al, 2017
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Use of Coumarin Anticoagulants and Cerebral Microbleeds in the General Population
Stroke 45:3436-3439, Akoudad, S.,et al, 2014
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Headache and Pregnancy
The Neurologist 14:108-119, Menon,R. &Bushnell,C.D., 2008